iShares Russell 2000 ETF (IWM)

Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

As of March 12, 2026, the U.S. stock market presents a jarring paradox that has left seasoned analysts sounding the alarm. While the flagship S&P 500 (NYSE: SPY) recently flirted with the historic 7,000 milestone and the Dow Jones Industrial Average (NYSE: DIA) remains within striking distance

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million.

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.

A White House official said that any policy announcement would come directly from the president, as per a Bloomberg News report.

The cloud software company posted Q4 results on Tuesday, with revenue coming in at $79.6 million, higher than consensus estimates of $79.03 million.

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.

The company said its revenue was $132.7 million in the fourth quarter 2025, below analyst expectations of $136.7 million, as per data from Fiscal.ai.

Freedom Capital initiated coverage of Critical Metals with a ‘Buy’ rating and $15 price target, representing an upside of almost 50% from its current price levels.

Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.

For the fourth quarter, Zevra announced net revenue of $34.1 million, exceeding an analyst estimate of $28.05 million.

The company announced its decision following a meeting with the U.S. Food and Drug Administration.

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

In the first quarter of 2026, the financial markets have undergone a definitive "regime change" that many analysts are calling the "Great Convergence." After years of an increasingly narrow market led by a handful of mega-cap technology giants, the tide has finally turned. The iShares Russell 2000 ETF (NYSE: IWM)

The sharp rally has piqued retail traders’ interest in the conservative-leaning news network.

Rosenblatt lowered the firm's price target on Webull to $12 from $15 and kept a ‘Buy’ rating on the shares, per TheFly.

As per Dorsey, any growth at Serve Robotics will fall short of investor expectations for multiple reasons.